Silverback Therapeutics Inc • SPRY

Capital at risk.

About Silverback Therapeutics Inc
Ticker
info
SPRY
Trading on
info
NASDAQ
ISIN
info
US82835W1080
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Richard Lowenthal M.B.A., M.S., MSMSEL
Headquarters
info
11682 El Camino Real, San Diego, CA, United States, 92130
Employees
info
155
Website
info
https://ars-pharma.com
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Metrics
BasicAdvanced
Market cap
info
$1.29B
P/E ratio
info
157.5
EPS
info
$0.08
Dividend Yield
info
0.00%
Beta
info
1.41
Forward P/E ratio
info
0
EBIDTA
info
$-3M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.29B
Average daily volume
info
2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
157.5
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
157.5
Price to sales
info
14.47
Price to book
info
5.02
Earnings
EPS
info
$0.08
EPS estimate (current quarter)
info
-$0.12
EPS estimate (next quarter)
info
-$0.20
EBITDA
info
$-3M
Revenues (TTM)
info
$89.1M
Revenues per share (TTM)
info
$0.92
Technicals
Beta
info
1.41
52-week High
info
$18.51
52-week Low
info
$7.55
50-day moving average
info
$12.12
200-day moving average
info
$12.34
Short ratio
info
15.06
Short %
info
37.04%
Management effectiveness
ROE (TTM)
info
3.28%
ROA (TTM)
info
0.66%
Profit margin
info
8.97%
Gross profit margin
info
$68.6M
Operating margin
info
54.51%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
4,900.00%
Share stats
Outstanding Shares
info
98.1M
Float
info
47.5M
Insiders %
info
22.97%
Institutions %
info
75.16%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$29.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.11
-$0.11
-
Q1 • 24Beat
-$0.13
-$0.12
8.33%
Q2 • 24Beat
-$0.20
-$0.15
33.33%
Q3 • 24Beat
$0.51
-$0.12
534.04%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$2.1M
$-19.1M
924.95%
Q3 • 24
$86.6M
$49.9M
57.67%
Q4 • 24
4,086.70%
361.05%
106.24%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$218M
$16.6M
7.64%
Q3 • 24
$351M
$94.4M
26.87%
Q4 • 24
61.37%
467.62%
251.74%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-14.5M
$16.8M
$0.7M
$-14.6M
Q3 • 24
$42M
$-102M
$70.9M
$41.7M
Q4 • 24
390.34%
705.07%
10,328.82%
385.49%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.64

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Silverback Therapeutics Inc share?
Collapse

Silverback Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Silverback Therapeutics Inc have?
Collapse

Silverback Therapeutics Inc currently has 98.1M shares.

Does Silverback Therapeutics Inc pay dividends?
Collapse

No, Silverback Therapeutics Inc doesn't pay dividends.

What is Silverback Therapeutics Inc 52 week high?
Collapse

Silverback Therapeutics Inc 52 week high is $18.51.

What is Silverback Therapeutics Inc 52 week low?
Collapse

Silverback Therapeutics Inc 52 week low is $7.55.

What is the 200-day moving average of Silverback Therapeutics Inc?
Collapse

Silverback Therapeutics Inc 200-day moving average is $12.34.

Who is Silverback Therapeutics Inc CEO?
Collapse

The CEO of Silverback Therapeutics Inc is Richard Lowenthal M.B.A., M.S., MSMSEL.

How many employees Silverback Therapeutics Inc has?
Collapse

Silverback Therapeutics Inc has 155 employees.

What is the market cap of Silverback Therapeutics Inc?
Collapse

The market cap of Silverback Therapeutics Inc is $1.29B.

What is the P/E of Silverback Therapeutics Inc?
Collapse

The current P/E of Silverback Therapeutics Inc is 157.5.

What is the EPS of Silverback Therapeutics Inc?
Collapse

The EPS of Silverback Therapeutics Inc is $0.08.

What is the PEG Ratio of Silverback Therapeutics Inc?
Collapse

The PEG Ratio of Silverback Therapeutics Inc is null.

What do analysts say about Silverback Therapeutics Inc?
Collapse

According to the analysts Silverback Therapeutics Inc is considered a buy.